Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI / SSE: 600329)

Deep Dive Research Report

SECTION 1: WHAT THE COMPANY DOES

Tianjin Pharmaceutical Da Ren Tang Group is a traditional Chinese medicine (TCM) manufacturer that researches, develops, processes, and sells Chinese patent medicines and herbal preparations. In plain terms, it takes ancient formulas - some protected by the state, some held exclusively by the company for generations - and turns them into finished pills, ointments, capsules, and dripping pills that Chinese consumers use to treat cardiovascular disease, respiratory conditions, skin injuries, and chronic illness. As of late 2024, the company shed its pharmaceutical distribution arm and became a focused pure-play TCM industrial manufacturer. Its products are made in Tianjin and sold primarily across China, with limited but growing international exposure.

The founding story and why it matters now

The heritage is not corporate window dressing - it defines the product moat. In 1522, a healer named Le Liangcai settled in Beijing and began systematizing classical TCM knowledge. Over three centuries, successive family generations built and refined pharmaceutical enterprises. In 1833, Long Shun Rong Pharmacy was established. In 1915, Le Daren - who had studied at Germany's Bayer Pharmaceutical Factory - founded Da Ren Tang Pharmaceutical Factory on Dajing Road in Tianjin. This was deliberate modernism applied to ancient formulas: Le Daren designed the factory along Bayer's industrial principles, covering over 8,000 square meters, making Da Ren Tang one of China's first modern pharmaceutical enterprises. In 1921, Le Youshen established Le Ren Tang.

The critical implication: the company's most important products are formulas that have existed for decades or centuries and that cannot be replicated by competitors without the same institutional knowledge. The Suxiao Jiuxin Wan (literally "fast-acting heart-saving pill") formula is a state-protected compound. Jingwanhong Ointment holds national trade-secret status as a "confidential variety." These protections are permanent, not patent-term-limited, which means no generic entry.

The group holds four China Time-honored Brand Enterprise designations (Da Ren Tang, Long Shun Rong, Le Ren Tang, Ching Wan Hung), five National Intangible Cultural Heritage designations, and six Chinese Well-known Trademarks. In 1997, it listed on the Singapore Exchange (SGX: T14), and in 2001 on the Shanghai Stock Exchange (SSE: 600329).

The 2020 turning point: mixed ownership reform

Between 2020 and 2022, the controlling shareholder - state-owned Tianjin Pharmaceutical Holdings - implemented a mixed ownership reform (混改), bringing in private-sector management practices. New leadership was installed. The sales organization, which had been structured around regional branches, was demolished and rebuilt along product-line divisions: a medical channel division, a retail division, an e-commerce division, and an international markets division. Salaries were reset to market median levels with annual upward adjustments. The transformation began to show in 2022, when the flagship Suxiao Jiuxin Wan exceeded RMB 1.5 billion in annual sales with 17.7% growth - the first full operating year under the reformed structure.

In 2022, the company was renamed from Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to its current name, signaling a deliberate identity shift back to heritage and away from the bland holding-company name it had carried.

The value proposition

The company offers something competitors cannot replicate quickly or cheaply: state-protected and secret formulas backed by centuries of documented efficacy, sold under brands that Chinese consumers and physicians have trusted for generations. For an elderly patient with angina who reaches for Suxiao Jiuxin Wan, the brand association and trust dynamic is functionally irreplaceable. For a physician prescribing to a patient, 75 of the company's products appear in the National Essential Medicine Catalogue and 279 are covered by national medical insurance - removing price sensitivity at the prescription stage.

The concrete product in action: a patient in a rural Hebei hospital experiences an episode of stable angina. The chest pain center's protocol, built in part through Da Ren Tang's "China Heart - Healthy Journey" educational campaigns (106 of which were run in 2024), calls for Suxiao Jiuxin Wan. The pill dissolves within minutes - it is a dripping-pill format for rapid absorption. The patient scans the QR code on the bottle and can trace the formula's journey from a GAP-certified herb plantation through processing, quality testing, and packaging. The manufacturer's name on the bottle - Da Ren Tang - is a 110-year-old brand. That is the full stack this company sells.

SECTION 2: BUSINESS SEGMENTS

As of end-2024, following the deconsolidation of the pharmaceutical commerce business, the company operates primarily as one segment: pharmaceutical manufacturing (the industrial segment). The prior commercial distribution segment and the Western medicine joint venture both moved outside the consolidated perimeter during 2024. Understanding all three former segments is necessary to grasp the current structure.

2.1 Pharmaceutical Manufacturing (Industrial Segment) - The Core

This is now the entire company. The industrial segment manufactures Chinese patent medicines, herbal preparations, chemical pharmaceutical products, and health products across six principal manufacturing subsidiaries in Tianjin. Products address cardiovascular and cerebrovascular disease, skin wound repair, premium health preservation, respiratory conditions, digestive ailments, rheumatism, gynecological conditions, pediatrics, oncology, and urology.

What makes this segment difficult to replicate is the intersection of four things: ancient formulas (some state-secret, some exclusively owned), brand associations built over a century, a manufacturing capability for complex multi-ingredient herbal formulations, and deep institutional relationships with China's medical system. The company holds 599 approved drug licenses covering 22 preparation types, with 114 varieties exclusively produced. That exclusivity list is the most defensible part of the business.

The segment was reorganized under the "Three Core, Nine Wings" (三核九翼) framework in 2022-2023. The Three Cores are the highest-priority products with the most brand recognition and clinical differentiation. The Nine Wings are specialty products in secondary therapeutic areas. This structure clarified marketing investment allocation and R&D priority for the first time in the company's modern history.

Gross margins in this segment are structurally high - in the 70%+ range for key patent medicines - because the manufactured value is concentrated in intellectual property (formulas, brand) rather than raw materials or capital intensity. The limiting factors on margin are raw herb cost volatility and distribution costs.

This segment was generating approximately 61% of consolidated revenues before the commerce deconsolidation, and now represents essentially all consolidated revenue.

2.2 Pharmaceutical Commerce (Deconsolidated Late 2024)

For most of the company's recent history, it operated Tianjin Zhongxin Medicine Co., a pharmaceutical distribution subsidiary that wholesaled and retailed both the group's own products and third-party pharmaceuticals across China. This was a high-volume, lower-margin business - gross margins in the single digits versus the industrial segment's 70%+.

In October 2024, shareholders approved the transfer of Tianjin Zhongxin Medicine into Jinyao Taiping Pharmaceutical Co., a joint venture with the parent Tianjin Pharmaceutical Holdings holding 56.65% and Da Ren Tang holding 43.35%. The transaction completed in December 2024. Post-transaction, this business is no longer consolidated - it is accounted for as an associate using the equity method.

The strategic logic is straightforward: the commerce business was dragging blended margins down and consuming management attention for a low-differentiation activity. The industrial segment is where the brand value and pricing power live. The separation was also a prerequisite for making the company's results legible to investors who care about the quality of the pharmaceutical manufacturing business.

The deconsolidation creates a significant optical revenue decline in 2025 (H1 revenue down 33% on a consolidated basis), which is mechanical, not operational. The industrial segment's revenues were essentially flat year-on-year in H1 2025.

2.3 Western Medicine Joint Venture (Disposed 2024-2025)

For decades, the company held equity in Sino-American Tianjin Smith Kline & French Laboratories Ltd. (TSKF), a joint venture established in 1987 with what became GlaxoSmithKline, and subsequently Haleon after Haleon's demerger. TSKF manufactures well-known consumer health products in China. The company was not the operator of this JV - it was a minority financial partner.

In December 2024, Da Ren Tang disposed of a 13% equity stake to Haleon China Co. for approximately RMB 1.71 billion in proceeds, generating a one-time gain that dominates the 2024 profit figure. In April 2025, the remaining 12% stake was sold to Haleon for a further RMB 1.6 billion. The exit is now complete: Haleon controls 88% of TSKF. Da Ren Tang has fully monetized this legacy holding, accumulated capital to reinvest, and simplified its structure to a pure TCM manufacturer.

The combined TSKF proceeds represent a multi-billion yuan cash injection that funds the 300 million yuan intelligent workshop investment and affords the company a strengthened balance sheet for the brand-building phase ahead.

Segment Summary

SECTION 3: PRODUCTS AND BUSINESS DETAIL

The Three Cores

Core 1: "China Heart" - Cardiovascular and Cerebrovascular

The flagship of the entire company is Suxiao Jiuxin Wan (速效救心丸), literally the "fast-acting heart-saving pill." This is a compound formula containing borneol and Ligusticum chuanxiong, combined to produce vasodilatory effects that relieve angina attacks within minutes. It is classified as a state-protected "national variety," which means no other manufacturer can legally produce the identical formula. The dripping-pill form factor - a spherical wax-coated tablet that dissolves rapidly under the tongue - was developed to accelerate absorption compared to conventional compressed tablets.

The product holds a Russian prescription drug registration obtained in 1997, making it one of the first TCM products to pass the Russian regulatory process. It has also obtained certifications recognized in Australia and Japan. In China, the product has achieved 81% coverage of hospital chest pain centers - the specialized cardiac emergency departments that are the primary prescription channel for acute cardiac events. The company ran 106 "China Heart - Healthy Journey" educational campaigns at chest pain centers in 2024 to deepen physician relationships. Market data shows the product ranked third in its therapeutic category in 2023 and rose to second place in 2024, with market share growing for five consecutive years since 2020. The company is removing "Tianjin" from packaging to brand it as a national rather than regional product.

The cardiovascular portfolio also includes Tongmai Yangxin Wan from Le Ren Tang (a compound tablet for coronary artery disease and nervous system symptoms), multiple dripping pills from the Sixth TCM Factory, and approximately eight exclusive drug licenses within the cardiovascular field.

Core 2: "China Skin" - Skin Wound Repair

Jingwanhong Ointment (京万红软膏, also sold internationally as Ching Wan Hung / Jing Wan Hong) is a burn and wound treatment ointment that has been in continuous production for decades. It is designated a state "confidential variety" - meaning the formula has national trade-secret protection rather than a standard patent filing, preventing reverse-engineering by competitors. The ointment contains a complex blend of 34 Chinese herbal ingredients including safflower, frankincense, myrrh, and rhubarb, formulated to reduce inflammation, remove necrotic tissue, and accelerate healing.

The product is used in burn wards, for pressure ulcer management, and for general wound care. International versions are sold in overseas Chinese communities across Southeast Asia and North America as an over-the-counter topical remedy. The Ching Wan Hung brand (the international transliteration) has its own century-old identity.

In 2024, the Jingwanhong manufacturing subsidiary received an FDA warning letter. Inspectors visiting the Tianjin Darentang Jingwanhong Pharmaceutical facility in March 2024 documented several violations: manufacturing areas were restricted to inspectors, records were provided with unreasonable redactions, filling machines (ID-192 and ID-197) appeared dirty and in disrepair despite being marked clean, and stability-indicating analytical methods were absent. An Import Alert (66-40) was placed on products from this facility in August 2024. This effectively blocks US market entry for Jingwanhong products until the company demonstrates corrective action and passes reinspection.

Beyond the traditional ointment, the company extracted from Jingwanhong's active compounds a novel cosmetic ingredient called "Jingwanhong Skin Renewal Factor" (京万红焕肤因子) and launched the "Shurun Anfu" (舒韧安肤) skincare cosmetics series in July 2025, targeting sensitive skin consumers. This is the company's first significant move into the consumer skincare market and represents a potential second revenue runway from the same underlying IP.

The skin segment holds eight topical skin drug licenses at the group level.

Core 3: "China Brain" - Premium Health Preservation

The third core centers on premium TCM preparations used for cognitive health, anti-aging, and general constitution strengthening. The lead products are Niuhuang Qingxin Wan (牛黄清心丸, a classical formula containing bezoar, pearl, and cinnamon for neurological and cardiac functions) and Qinggong Shoutao Wan (清宫寿桃丸, a Qing Dynasty imperial court formula for longevity and cognitive preservation). These sit at the premium end of the market, sold primarily as health maintenance products to older consumers and as gifts.

Bezoar (牛黄, gallstones from cattle) is one of the rarest and most expensive TCM ingredients; some of the company's formulations use artificial bezoar as a partial substitute, which has regulatory and quality implications. These products are positioned partly on heritage (Qing Dynasty imperial court provenance) and partly on the growing demand from China's aging population for cognitive health products.

The Nine Wings

The Nine Wings cover specialty therapeutic areas where the company has heritage products and market positions but where no single product dominates the way Suxiao Jiuxin Wan dominates its category:

• Respiratory: Qingyan Dripping Pills (清咽滴丸, throat soother and anti-inflammatory) is the standout product here. It delivered 52% growth in H1 2025, driven by campaigns including the release of a "China Throat Health White Paper" and branded educational activities at 20 cities. Yangyin Qingfei Syrup (养阴清肺膏, from Le Ren Tang) addresses dry-type respiratory conditions.
• Digestive: Huoxiang Zhengqi Soft Capsules (a digestive regulator for summer heatstroke and gastrointestinal complaints) and Xiao'er Hewei Pills (children's digestive formula).
• Rheumatism and orthopedics: Multiple bone and joint formulations from the Sixth TCM Factory.
• Gynecology and pediatrics: A range of women's health formulas.
• Oncology: Xihuang Pills (from Le Ren Tang, a classical anti-tumor formula containing musk, bezoar, frankincense, and myrrh), and Zilongjin (an anticancer preparation from Long Shun Rong).
• Diabetes and metabolic: Jinqi Jiangtang Tablets from Long Shun Rong (one of the few TCM products with established clinical evidence for blood glucose control in type-2 diabetes).
• Urology: Long Shun Rong's specialist formulations.

Manufacturing Infrastructure

The company operates six principal manufacturing subsidiaries in Tianjin, each with its own heritage and specialty:

• Da Ren Tang Pharmaceutical Factory (1915): General TCM pills and capsules. Products include Qingfei Xiaoyan Pills and Qinggong Shoutao Wan.
• Long Shun Rong Pharmaceutical Factory (1833): Specializes in diabetes and urology. China's oldest continuously operating commercial pharmacy.
• Le Ren Tang Pharmaceutical Factory (1921): Cardiovascular and respiratory. Produces Tongmai Yangxin Pills and Xihuang Pills.
• The Sixth Traditional Chinese Medicine Factory (1958): National demonstration base for dripping-pill quality management. Dripping pills require precise temperature control and formulation chemistry - this factory has 65+ years of accumulated process knowledge in that format.
• Ching Wan Hung Pharmaceutical: Produces Jingwanhong Ointment and associated topical/digestive formulations.
• Xinxin Pharmaceutical Factory (1961): Endocrine, metabolic, and cardiovascular drugs with more than 10 varieties across 40+ specifications.

The facilities collectively hold 599 approved drug licenses across 22 preparation types (pills, soft capsules, dripping pills, ointments, syrups, granules, etc.).

The company is investing over RMB 300 million in a next-generation intelligent workshop that will use near-infrared spectroscopy for in-process quality control and automated visual inspection systems. The stated objective is to address batch-to-batch variation - a structural challenge in herbal medicine manufacturing where raw material composition varies by harvest season, geography, and storage. Each finished product already carries a QR code enabling full traceability from herb plantation through processing and quality control.

The company operates its own GAP (Good Agricultural Practice) herb cultivation bases, as documented in its 2023 sustainability filings, which allows some control over raw material quality upstream.

Geography

Sales are overwhelmingly domestic China. Exports cover 12+ countries. The most established international markets are Russia (Suxiao Jiuxin Wan prescription registration since 1997), Australia, and Japan. In 2024, 12 products were registered in Singapore, 2 received approval in Hong Kong, and 18 varieties obtained HALAL certification for Muslim markets. The Singapore subsidiary (Tianjin Pharmaceutical Da Ren Tang Singapore Development Co. Pte. Ltd.) handles regional Southeast Asian distribution. International revenue remains a small fraction of total sales, but the company is actively expanding its regulatory registrations.

SECTION 4: CUSTOMERS

The Medical Channel

The primary customers for core cardiovascular and specialty products are hospitals and their pharmacies. The buying decision sits with multiple stakeholders: clinical pharmacists who build formularies, cardiologists and internists who write prescriptions, and hospital procurement administrators who manage bidding tenders. The company completed 243 bidding and tender projects covering 149 products across 34 provinces in 2024, which is the essential front door to the hospital market. If a product is not on a provincial tender list, it effectively cannot be sold to that province's hospital system.

The 75 products on the National Essential Medicine Catalogue are particularly important here. Essential Medicine status means provincial governments are required to stock these products in government health facilities, and reimbursement rates are set at favorable levels. For Suxiao Jiuxin Wan, achieving 81% coverage of chest pain centers is a direct measure of medical channel penetration - it means that in 81% of the specialist cardiac emergency units across China, the product is already on formulary and available for immediate use.

Physician education is a significant customer relationship investment. The 106 "China Heart - Healthy Journey" campaigns in 2024 are educational forums at chest pain centers where the company discusses the clinical evidence for Suxiao Jiuxin Wan, builds relationships with cardiologists, and keeps the product top of mind. Switching costs in the medical channel are high: once a product is on a hospital formulary and physicians are trained to use it, replacement requires a new tender process, new formulary review, and re-education.

The Retail/OTC Channel

Many of the company's products, particularly Suxiao Jiuxin Wan, Qingyan Dripping Pills, and Jingwanhong Ointment, are sold OTC in pharmacy chains, convenience pharmacies, and increasingly through e-commerce. Here the buyer is a consumer self-selecting based on brand recognition, pharmacist recommendation, or repeat purchase.

Brand recognition is the critical switching cost in the retail channel. A consumer who grew up in a household that used Suxiao Jiuxin Wan is unlikely to switch to an unfamiliar brand even at a lower price - the stakes (cardiac emergency) are too high. The company is explicitly targeting this dynamic by investing in brand activities including flagship stores and digital campaigns designed to associate the brands with younger, health-conscious demographics, not only the elderly patients who have historically been the core users.

The company is shifting from "broad distribution to deep penetration" in key markets including the Pearl River Delta and Yangtze River Delta, meaning fewer but higher-quality retail partnerships with dedicated shelf space and promotional support rather than blanket wholesale distribution.

Customer Concentration

The company does not have meaningful customer concentration risk in the sense of a single customer driving a large share of revenue. The distribution is across thousands of hospitals, pharmacy chains, and individual pharmacies. This is typical for consumer healthcare / OTC pharmaceutical businesses. The key concentration risk is at the regulatory level: the National Medical Security Administration's reimbursement list and the Essential Medicine Catalogue represent policy gatekeepers whose decisions can affect entire product categories simultaneously.

Contract Structure

Hospital sales are governed by provincial tender contracts, typically multi-year in duration but subject to re-tender cycles. Retail sales are mix of direct agreements with pharmacy chains and wholesale distributor arrangements. International markets operate through long-term registration and distribution agreements with local partners.

SECTION 5: COMPETITIVE LANDSCAPE

The TCM manufacturing industry in China is structurally fragmented. The top four companies - Beijing Tongrentang, China TCM, Kangmei, and Tasly - together account for only approximately 10% of total industry revenue, according to IBISWorld's 2025 data. This fragmentation reflects the breadth of the category: there are thousands of approved TCM formulas, many producing different therapeutic outcomes, and no single player has managed to dominate across categories. Da Ren Tang does not compete against all TCM manufacturers - it competes for dominance in its specific therapeutic niches.

Beijing Tongrentang (同仁堂): The most famous name in TCM globally. Tongrentang is more upmarket, more focused on premium health tonics and premium gift products (ginseng, deer antler, bird's nest preparations), and has a stronger international retail presence. The two companies have overlapping product categories in cardiovascular and premium TCM but Tongrentang skews toward wealthier, gift-buying consumers. Da Ren Tang competes with Tongrentang on premium heart health products and some wellness formulas but not on the mass OTC emergency cardiac medicine market, where Suxiao Jiuxin Wan is the category leader. Tongrentang does not produce a direct equivalent.

Tasly Pharmaceutical (天士力): Tasly is the most relevant direct competitor in the cardiovascular TCM space. Its Compound Danshen Dripping Pills (复方丹参滴丸) - a different formula addressing angina and coronary heart disease - directly competes with Suxiao Jiuxin Wan for prescriptions and OTC purchase. Tasly has historically invested heavily in clinical trials and once pursued FDA approval for its Compound Danshen Dripping Pills (a process that was ultimately not completed). Tasly's product was the cardiovascular TCM market leader for many years. The fact that Suxiao Jiuxin Wan rose from third to second place in 2024 suggests Da Ren Tang is winning share, possibly benefiting from the 2020 management reforms and intensified physician education campaigns. However, Tasly remains a well-capitalized competitor with strong brand recognition.

Yunnan Baiyao (云南白药): Strongest in the wound care category. Its flagship Yunnan Baiyao powder and Yunnan Baiyao Band-Aids are dominant in trauma wound care and hemostasis. This is a different use case than Jingwanhong (burns, pressure ulcers, chronic wounds), so the two companies do not directly compete head-to-head. However, in the broader "external wound care" market, Yunnan Baiyao's brand dominance creates a ceiling on how much consumer mind-share Jingwanhong can capture. The FDA warning letter on Jingwanhong is particularly damaging relative to Yunnan Baiyao, which has maintained quality compliance and international ambitions more carefully.

CR Sanjiu (三九医药): Known for 999 Cold Remedy Granules and a range of respiratory and digestive OTC products. Overlapping with Da Ren Tang's Nine Wings in respiratory and digestive areas, but Sanjiu's scale in consumer OTC gives it strong retail channel relationships that Da Ren Tang is still building out.

Barriers to entry

The key barrier in this industry is not capital or manufacturing technology - those are accessible to any competent pharmaceutical manufacturer. The genuine barriers are:

1. State-protected formulas: Competitors cannot legally manufacture Suxiao Jiuxin Wan or Jingwanhong. These protections do not expire. New entrants cannot circumvent them.
2. Heritage brand trust: In therapeutic categories where efficacy is difficult for a patient to verify quickly (cardiovascular prevention, cognitive health), brand heritage functions as a proxy for safety. A 100-year-old brand with imperial court provenance cannot be replicated in five years.
3. Medical channel relationships: Getting onto provincial tender lists, onto hospital formularies, and into chest pain center protocols requires years of clinical education investment and regulatory approval processes. The company's 81% chest pain center coverage represents roughly a decade of accumulated commercial work.
4. National Essential Medicine Catalogue and insurance coverage: Both barriers to entry and moats. A competitor needs clinical data, regulatory approval, and negotiation with NMPA and medical security administrations to get similar coverage - a multi-year process.

Where Da Ren Tang is exposed: in the Nine Wings specialty areas, most products do not have the same state-protection or brand dominance that the Three Cores enjoy. Competitors with similar formulas can and do compete. In the cosmetics extension of Jingwanhong, the barriers are much lower: any cosmetics company can develop a TCM-infused skincare line, and Yunnan Baiyao has already moved in this direction.

SECTION 6: INDUSTRY

What drives demand

Demand for Da Ren Tang's core products is driven by demographics, the rising prevalence of chronic disease in China, and government policy.

China's cardiovascular disease burden is large and growing. The country has over 330 million patients with cardiovascular disease, a figure that continues to rise with aging demographics and the cardiovascular effects of historically high smoking rates. The National Essential Medicine Catalogue policy ensures that TCM cardiovascular products have subsidized access and strong reimbursement - government policy explicitly supports TCM as a complement to Western medicine.

For skin wound care, demand is driven by an aging population (pressure ulcers are a common geriatric problem), hospital burn units, and the emerging consumer interest in TCM-based skincare. The Chinese government launched "Healthy China 2030" policies that explicitly promote TCM for chronic disease management, which benefits the entire category.

Industry size and structure

The global TCM market was valued at approximately USD 250 billion in 2024 and is growing at roughly 7.5% CAGR to 2033, per multiple market research sources. Within China, the domestic TCM manufacturing industry generates approximately USD 41 billion annually (2025 estimate, IBISWorld). The industry is fragmented: no player holds more than a few percent of total market share in this broad category.

China's government support

This is the single most important structural tailwind. The Chinese government:

• Includes 75+ Da Ren Tang products on the National Essential Medicine Catalogue
• Covers 279 Da Ren Tang products under national medical insurance
• Classifies Da Ren Tang as a "national high-tech enterprise," enabling R&D tax incentives
• Protects specific formulas at the state level through confidential variety and national variety designations
• Has built out thousands of TCM clinics and integrated TCM into its public health system

The "Healthy China 2030" initiative, launched in 2019, explicitly targets TCM promotion as a national healthcare priority. This is structural, not cyclical. Policy risk cuts both ways, however - insurance reimbursement rate changes or removal from essential medicine catalogues would directly impact demand.

Regulatory environment

The National Medical Products Administration (NMPA) governs drug approval in China. TCM approvals are in theory held to the same safety and efficacy standards as Western medicine, though the evidentiary frameworks differ. In practice, state-protected formulas and national varieties face a lower commercial risk of regulatory revision because of their political and cultural status.

Internationally, the regulatory environment is significantly harder. The FDA's approach to TCM is skeptical: without randomized controlled trial data meeting FDA standards, Chinese herbal medicines are typically classified as dietary supplements rather than drugs in the US. The Jingwanhong subsidiary's FDA warning letter in 2024 reflects both the difficulty of navigating FDA inspections and the company's internal manufacturing compliance gaps in that specific facility.

Cyclicality

TCM for chronic cardiovascular conditions and emergency cardiac care is among the least cyclical products a healthcare company can make. People do not cut back on angina medication in a recession. The premium health preservation products (Core 3) have some cyclicality in the gifting channel - discretionary purchasing slows in economic downturns - but the core products are essentially acyclical.

Global tailwinds

A Xinhua report in January 2026 noted growing international interest in TCM, with Chinese medicine cultural centers expanding across Southeast Asia, Central Asia, and parts of Africa. HALAL certification for 18 of Da Ren Tang's varieties opens a potential pathway into Islamic-majority markets with large populations (Indonesia, Malaysia, Middle East). The company's Singapore listing has always served partly as a gateway to Southeast Asian capital and brand awareness.

SECTION 7: GROWTH TRIGGERS

Note on sources: This company does not conduct formal Western-style quarterly earnings calls. It participates in SSE-hosted collective investor briefings (typically twice per year), provides AGM question responses, and engages with shareholders on the SSE interactive platform (互动易). The closest equivalents to concall transcripts are the annual and semi-annual results briefings and shareholder Q&A records. The following triggers are extracted from these sources, primarily from the 2023 annual results briefing (May 2024), the 2024 annual report (March 2025), the 2025 H1 report and briefing (August 2025), and AGM 2025 proceedings (May 2025).

• Intelligent workshop commissioning: The company is investing over RMB 300 million in a next-generation manufacturing facility using near-infrared spectroscopy and automated visual inspection systems. This investment, described in multiple investor communications, is designed to standardize batch quality and enable capacity scale-up. Commissioning timeline has not been publicly specified, but the investment was described as underway in 2024-2025 communications. (2024 Annual Report; 2025 H1 briefing)

"The upcoming new generation intelligent workshop, with an investment exceeding 300 million yuan, will use near-infrared spectroscopy and visual inspection systems to further enhance precision." - Company communications, 2025

• Suxiao Jiuxin Wan market share expansion - national branding initiative: Management confirmed in the 2024 AGM and subsequent investor Q&A that the company is removing the word "Tianjin" from Suxiao Jiuxin Wan packaging to re-position it as a national brand rather than a regional one. Historically, the "Tianjin" prefix limited consumer perception in southern Chinese markets. This rebranding, combined with digital precision marketing campaigns, is expected to accelerate penetration in Pearl River Delta and Yangtze River Delta markets. (AGM 2025, May 2025; shareholder Q&A, 2024-2025)

• Qingyan Dripping Pills - respiratory category expansion: Management indicated in the 2025 H1 briefing that Qingyan Dripping Pills achieved over 52% year-on-year sales growth in H1 2025. The company launched a "China Throat Health White Paper" and branded health education campaigns across 20 cities. This product is now a stated growth priority within the Nine Wings, reflecting the company's shift from cardiovascular concentration toward a broader portfolio. (2025 H1 results)

• Jingwanhong cosmetics line launch: Management described in 2025 the development of "Jingwanhong Skin Renewal Factor" (京万红焕肤因子) and the launch of the "Shurun Anfu" skincare series in July 2025 targeting sensitive skin. The company simultaneously initiated the "Jingwanhong Academy Award" brand project reaching over one million students across 1,800 universities to seed brand awareness in younger demographics. (2025 H1 report and briefings)

• International market registrations advancing: The company announced in 2024 that 12 products were registered in Singapore, 2 products received Hong Kong approval, and 18 varieties obtained HALAL certification. These are prerequisite steps to monetization in new markets. Management described international as an incremental growth channel, not a near-term revenue driver. (2024 Annual Report)

• Portfolio R&D pipeline: Management disclosed in 2024 that the company completed 10 new product project initiations and 22 large-product secondary development projects, with an 80% milestone completion rate. The three-level R&D system (technical center reorganized) and departmental management structure were completed. This is a medium-term trigger - products in clinical development are 3-5 years from commercialization. (2024 Annual Report; shareholder briefing May 2024)

• Medical channel coverage expansion: The company achieved 81% coverage of hospital chest pain centers in 2024 for Suxiao Jiuxin Wan and completed 243 tender project wins across 149 products in 34 provinces. Continued expansion toward 100% chest pain center coverage and deeper penetration in currently underserved provinces is a stated commercial objective. (2024 Annual Report)

• Lung nodule treatment program: In response to an investor Q&A (confirmed in 2025 shareholder interactions), management disclosed participation in a "Four Major Chronic Diseases" research initiative using AI to develop treatment protocols for lung nodules, leveraging existing products like Yifei Qinghua paste. This is early-stage but signals a potential future indication expansion. (SSE shareholder Q&A, 2025)

SECTION 8: KEY RISKS

1. FDA Import Alert on Jingwanhong - International Market Closure Risk

In August 2024, the FDA placed Import Alert 66-40 on products from Tianjin Darentang Jingwanhong Pharmaceutical, effectively blocking entry of Jingwanhong products into the United States. The October 2024 warning letter documented manufacturing obstruction (restricted inspector access, redacted records, denied photography), dirty equipment in use, inadequate process validation, and absent stability-indicating analytical methods. Until the facility undergoes reinspection and demonstrates remediation, US market access is closed. Given that Jingwanhong Ointment is a flagship global brand sold in overseas Chinese communities internationally, and the company is simultaneously launching a cosmetics extension of the brand, this compliance failure directly undermines the international credibility of the company's most recognized export product. The risk is not limited to the US: FDA warning letters are publicly reported and can trigger regulatory scrutiny from other countries' agencies, particularly in markets like Australia and Canada where Da Ren Tang has registrations. This is a high-probability, ongoing drag on international expansion - not a catastrophic risk to the core domestic business, but a meaningful constraint on the international growth story.

2. National Medical Insurance Reimbursement Rate Cuts

China's National Medical Security Administration periodically renegotiates drug reimbursement rates in volume-based procurement (VBP) rounds and DRG/DIP (diagnostic-related group) payment system expansions. In recent years, VBP has primarily targeted generic Western pharmaceuticals, but TCM patent medicines are increasingly in scope. If Suxiao Jiuxin Wan or other core products face aggressive price reductions in reimbursement negotiations, margins compress without offsetting volume growth. The mechanism: the NMPA or NMSA sets a maximum reimbursable price; hospitals, guided by cost-control targets, shift prescriptions toward lower-cost alternatives; the company faces the choice of accepting the lower price or losing hospital channel access. This is a high-probability, moderate-magnitude risk that has played out across Chinese healthcare repeatedly. The protection here is that state-protected formulas have some political insulation from the most aggressive VBP rounds, but this protection is not absolute.

3. Single-Product Revenue Concentration

Suxiao Jiuxin Wan has historically represented approximately 40-45% of the industrial segment's revenue. This is a structurally significant concentration risk. Any adverse event - a competitor achieving a breakthrough cardiovascular TCM with superior clinical evidence, a clinical trial showing safety concerns with long-term borneol use, a raw material supply disruption, or a regulatory reclassification - would disproportionately impact the company. The Three Core Nine Wings strategy is the explicit management response to this risk, but the diversification is still early-stage; the second-largest product by revenue is a fraction of the flagship's scale. This risk is permanently present and should be held in mind when evaluating the premium placed on the company's heritage brands.

4. Pharmaceutical Commerce Deconsolidation - Transition Risk

The transfer of Tianjin Zhongxin Medicine into Jinyao Taiping and the resulting guarantee liability (approximately RMB 524 million in remaining guarantee obligations as of late 2024, valid until May 2026) represents a transitional contingent liability. If Jinyao Taiping's distribution business faces financial stress, Da Ren Tang is exposed proportionately through its 43.35% guarantee. The pharmaceutical distribution business operates on thin margins and is subject to working capital cycles that can produce liquidity stress. This is a low-probability, bounded risk given the parent company's oversight, but it is real and non-zero.

5. Raw Material Cost and Supply Volatility

TCM manufacturing depends on a diverse supply of medicinal herbs whose quality and price vary with climate, agricultural conditions, and supply chain dynamics. Borneol (a key Suxiao Jiuxin Wan ingredient) and bezoar (used in premium Core 3 products) are particularly sensitive. Artificial bezoar is a partial substitute but is viewed as inferior by traditional practitioners and may face regulatory distinctions. The company's GAP cultivation bases provide some upstream integration, but most raw material sourcing remains exposed to market price fluctuations. Historically, this has been an earnings volatility driver, particularly in years when herb prices spike due to drought or supply chain disruption.

6. Management Depth and Reform Continuity Risk

The 2020 mixed ownership reform brought in management that delivered Suxiao Jiuxin Wan's five-year growth streak and restructured the commercial business. The current chairwoman Wang Lei is executing the Three Core Nine Wings strategic plan. In state-owned enterprises with mixed-ownership structures, management continuity is not guaranteed - the state-owned parent retains the right to change leadership, and a change in management philosophy could undo the commercial reforms that have driven recent improvement. This is particularly relevant because the current management's private-sector practices (performance incentives, sales team restructuring, channel strategy) are not the default behavior of Chinese SOE management, and the cultural shift required to maintain them is ongoing.

SECTION 9: WALK THE TALK

An important caveat: This company does not conduct formal quarterly earnings calls. Its investor communication is through SSE collective briefings (typically twice annually), AGM proceedings, annual/semi-annual reports, and the SSE interactive platform for individual investor Q&A. The following management credibility assessment draws on these sources across approximately 2022-2025. Where specific quotes are available from dated proceedings, they are included.

2022-2023: The Reform Delivery Period

Following the 2020 mixed ownership reform, management made explicit commitments about restructuring the sales organization from regional branches to product-line divisions and improving incentives. These structural reforms were verifiably completed. The sales architecture now has dedicated medical, retail, e-commerce, and international divisions - demonstrable from public organizational disclosures and subsequent product-level performance reporting. The reform was promised; the reform was delivered.

The early financial signal that the reform was working arrived in 2022, when Suxiao Jiuxin Wan exceeded RMB 1.5 billion in annual sales with 17.7% growth. Analyst briefings in 2022 were explicit that this product growth was attributable to the reorganized sales team and the inventory destocking of prior distribution channel excess. Management called these improvements accurately.

2023-2024: The Strategic Clarity Period

The Three Core Nine Wings framework was formalized and communicated to investors in 2022-2023. By the May 2024 briefing (covering FY2023 results and Q1 2024), management was reporting that Suxiao Jiuxin Wan's market ranking had improved (ultimately to second place by end-2024) and that secondary products including Qingyan Dripping Pills were gaining traction.

What management did not communicate clearly, or communicated only through separate corporate announcements rather than investor briefings, was the full scope of the corporate restructuring: the TSKF stake disposals and the pharmaceutical commerce deconsolidation. These were announced through SGX required-disclosure mechanisms (interested person transaction circulars, EGM notices) rather than through proactive investor briefings. The result was that the optical impact on revenues in 2025 - a 33% decline due to the commerce deconsolidation - was technically disclosed but not well-explained in advance in investor-facing language. This suggests management communicates operational performance reasonably well but is less transparent about structural change and its financial presentation impacts.

2024-2025: TSKF Disposal and Commerce Spinoff

The TSKF disposal executed in two stages (December 2024 and April 2025) was flagged in advance through regulatory announcements. Management told investors that the proceeds would be reinvested in the core industrial business, including the RMB 300 million intelligent workshop. This commitment is trackable - the intelligent workshop is public, ongoing, and frequently referenced in communications. No evidence exists of these proceeds being diverted to other purposes. Mark this as a promise in progress: the reinvestment commitment was made, and early execution is consistent with it.

In response to investor questions about the decline in cash flows from operations in 2025 Q3, management accurately explained that the deconsolidation of commerce subsidiaries (now joint ventures) mechanically reduced consolidated cash flow. This was an accurate and specific explanation, not deflection. Similarly, in Q&A around changes in accounts receivable and inventory in the 2024 annual report, management correctly attributed the changes to the commerce spinoff. The operational explanations have been factually accurate when tested.

The FDA warning letter gap

One area where management has not communicated proactively: the FDA warning letter on Jingwanhong (October 2024) does not appear in SGX or SSE investor briefing materials as a prominently flagged risk item. This is a significant international market impact event for one of the company's heritage brands, and it deserved explicit investor communication beyond the required regulatory disclosure. Its absence from briefing materials suggests management either underweights international market risk or chose to minimize attention to it.

Overall assessment: This is a management team that has delivered on the operational restructuring commitments made in 2020-2022 and that communicates financial and product results accurately when directly questioned. The track record on core product performance - Suxiao Jiuxin Wan's five-year market share improvement - reflects honest and successful execution. However, management is reactive rather than proactive in disclosing structural changes and their financial presentation impacts, and has been notably quiet on the FDA compliance issue that affects an important brand. They do what they say on operations; they are sometimes slow to volunteer what they haven't yet solved.

SECTION 10: SCENARIOS

Bull Case: "The TCM National Champion Emerges"

In the bull case, the Three Core Nine Wings strategy achieves what management intends: a few heritage products become genuinely national brands rather than strong regional or category-specific products. Suxiao Jiuxin Wan, rebranded without the "Tianjin" designation, breaks out of its northeastern China heartland and achieves strong penetration in southern China's larger consumer markets. The Qingyan Dripping Pills trajectory - 52% growth in H1 2025 - continues as the "China Throat Health" campaign takes root, and the brand becomes the respiratory TCM equivalent of a household name.

The intelligent workshop completes commissioning in 2025-2026, resolves the batch variation challenge that has historically constrained manufacturing consistency, and allows capacity scale-up without proportionate cost increases. Gross margins in the industrial segment expand as the high-margin core products grow faster than the mix.

The Jingwanhong cosmetics extension proves to be more than an experiment: the "Jingwanhong Skin Renewal Factor" cosmetics line captures a young female consumer demographic that the traditional pharmaceutical brand never accessed, opening a high-margin consumer goods revenue stream alongside the clinical wound care product. Jingwanhong remedies its FDA compliance deficiencies, clears reinspection, and re-enters the US market with both pharmaceutical and cosmetics positioning.

Internationally, the HALAL certification and Singapore registrations begin generating meaningful volume in Southeast Asia. China's Belt and Road cultural diplomacy continues to create favorable conditions for TCM brands in Central Asian and Middle Eastern markets.

The result: a pure-play TCM manufacturer that has successfully transitioned from regional SOE heritage company to consumer healthcare brand, commanding category leadership in cardiovascular TCM and a growing presence in skin health, without dependence on the commodity distribution business it shed.

Base Case: "Steady Improvement Behind the Restructuring Noise"

The restructuring-driven revenue optics stabilize in 2025-2026 as the commerce deconsolidation becomes the new baseline. The industrial segment's organic growth returns to mid-single-digit percentages annually, driven primarily by Suxiao Jiuxin Wan's continued market share gains (the product holds second place, makes gradual progress toward first) and Qingyan Dripping Pills continuing to outperform. The Three Core Nine Wings framework brings discipline to marketing investment but the Nine Wings remain a collection of solid but not dominant niche products.

The intelligent workshop investment completes and improves operational quality, but the benefits are primarily in cost stability and quality consistency rather than dramatic margin expansion. The Jingwanhong cosmetics extension finds a small but loyal consumer following and adds a new revenue line without displacing the core pharmaceutical business. FDA compliance issues at Jingwanhong are gradually remediated, but US market re-entry remains 2-3 years away.

The TSKF proceeds are partially invested in the intelligent workshop and partially returned to shareholders through dividends, supporting the company's already generous dividend track record. Management maintains stable execution of the current strategic plan without major new initiatives. The company is a reliable, growing TCM industrial business generating consistent cash flows from state-protected formulas and heritage brands, without a dramatic re-rating catalyst.

Bear Case: "Policy Headwinds and Brand Erosion"

In the bear case, the National Medical Security Administration includes TCM patent medicines in the next volume-based procurement round, applying aggressive price reduction targets to core products including Suxiao Jiuxin Wan. The company faces the choice of accepting the lower reimbursement price (margin compression) or losing hospital channel access. Volume holds, but profitability shrinks.

Simultaneously, the Jingwanhong FDA compliance failure proves harder to remediate than management anticipated. The facility requires significant capital investment to meet CGMP standards. Other regulatory agencies in markets where Da Ren Tang has registrations become skeptical, triggering additional compliance reviews. The cosmetics extension of Jingwanhong launches into a skeptical market that associates the brand with pharmaceutical quality concerns, and the extension underperforms.

Tasly Pharmaceutical completes a significant clinical trial that demonstrates their Compound Danshen Dripping Pills' non-inferiority to standard-of-care Western medicine for stable angina, earning a medical guideline endorsement. Physician prescribing behavior shifts toward Tasly's product in the high-margin hospital channel, while Suxiao Jiuxin Wan retains the OTC consumer base but loses ground in the premium formulary segment.

The 43.35% guarantee exposure in Jinyao Taiping Pharmaceutical (the commerce joint venture) crystallizes partially when the distribution business faces working capital stress in a weak economic environment.

The result is a company still protected by its state-secret formulas but facing margin compression on multiple fronts simultaneously - pricing pressure from policy, competitive pressure from a clinical-evidence investment by a well-resourced rival, and brand credibility risk from the manufacturing compliance failure. Growth stalls, dividends are maintained at the cost of balance sheet flexibility, and the premium for heritage brands erodes.

Sources:

• Tianjin Pharmaceutical Da Ren Tang Group - Company Profile
• Group History Page
• Group Industry Operations Page
• FDA Warning Letter - Tianjin Darentang Jingwanhong Pharmaceutical (Oct 2024)
• Haleon Increases China JV Stake to 88%
• MarketScreener: Haleon Completes 33% TSKF Acquisition
• KGI Daily Research - Tianjin Pharmaceutical (Oct 21, 2024)
• SIAS Annual Report Archive - Tianjin Da Ren Tang
• 9FZT Analyst Report: 2024 Annual and 2025 Q1 Review
• Hexun: Three Core Nine Wings Strategy Analysis
• Hexun: Mixed Ownership Reform Analysis (Dec 2023)
• Xinhua: TCM Winning Global Hearts (Jan 2026)
• IBISWorld: Traditional Chinese Medicine Manufacturing in China
• Lixinger Shareholder Interactions Database - 600329
• Futunn: 达仁堂 focusing on core business analysis
• StockAnalysis: SGX:T14 Overview